Katrin I. Andreasson

Katrin I. Andreasson

Auto-generated profile, based on publicly available information

Katrin I. Andreasson

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2023 in Nature
Verified
Journal Article
Open access
PDF file
HOHamilton Se-Hwee Oh
Hamilton Se-Hwee Oh
JRJarod Rutledge
Jarod Rutledge
DNDaniel Nachun
Daniel Nachun
RPRóbert Pálovics
Róbert Pálovics
OAOlamide Abiose
Olamide Abiose
TWTony Wyss-Coray
Tony Wyss-Coray
Animal studies show aging varies between individuals as well as between organs within an individual1–4, but whether this is true in humans and its effect on age-related diseases is unknown. We utilized levels of human blood plasma proteins originating from specific organs to measure organ-specific aging differences in living individuals. Using machine learning models, we analysed aging in 11 major organs and estimated organ age reproducibly in five independent cohorts encompassing 5,676 adults across the human lifespan. We discovered nearly 20% of the population show strongly accelerated age in one organ and 1.7% are multi-organ agers. Accelerated organ aging confers 20–50% higher mortality risk, and organ-specific diseases relate to faster aging of those organs. We find individuals with accelerated heart aging have a 250% increased heart failure risk and accelerated brain and vascular aging predict Alzheimer’s disease (AD) progression independently from and as strongly as plasma pTau-181 (ref. 5), the current best blood-based biomarker for AD. Our models link vascular calcification, extracellular matrix alterations and synaptic protein shedding to early cognitive decline. We introduce a simple and interpretable method to study organ aging using plasma proteomics data, predicting diseases and aging effects.

9 December 2024 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MHMichael Thomas Heneka
Michael Thomas Heneka
WFWiesje M. van der Flier
Wiesje M. van der Flier
FJFrank Jessen
Frank Jessen
JHJeroen Hoozemanns
Jeroen Hoozemanns
DTDietmar Rudolf Thal
Dietmar Rudolf Thal
SRSean-Patrick Riechers
Sean-Patrick Riechers

23 September 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
AJAmit U. Joshi
Amit U. Joshi
PMParas S. Minhas
Paras S. Minhas
SLShane Liddelow
Shane Liddelow
BHBereketeab Haileselassie
Bereketeab Haileselassie
KAKatrin I. Andreasson
Katrin I. Andreasson
DMDaria Mochly-Rosen
Daria Mochly-Rosen

26 November 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PMParas S. Minhas
Paras S. Minhas
LLLing Liu
Ling Liu
PMPeter K. Moon
Peter K. Moon
AJAmit U. Joshi
Amit U. Joshi
CDChristopher Dove
Christopher Dove
KAKatrin I. Andreasson
Katrin I. Andreasson

20 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
PMParas S. Minhas
Paras S. Minhas
ALAmira Latif-Hernandez
Amira Latif-Hernandez
MMMelanie R. McReynolds
Melanie R. McReynolds
ADAarooran S. Durairaj
Aarooran S. Durairaj
QWQian Wang
Qian Wang
KAKatrin I. Andreasson
Katrin I. Andreasson

23 August 2024 in Science
Verified
Journal Article
Closed access
PMParas S. Minhas
Paras S. Minhas
JJJeffrey R. Jones
Jeffrey R. Jones
ALAmira Latif-Hernandez
Amira Latif-Hernandez
Yuki SugiuraYuki Sugiura
Yuki Sugiura
ADAarooran S. Durairaj
Aarooran S. Durairaj
KAKatrin I. Andreasson
Katrin I. Andreasson
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer’s disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. Activation of astrocytic IDO1 by amyloid β and tau oligomers increases KYN and suppresses glycolysis in an aryl hydrocarbon receptor–dependent manner. In amyloid and tau models, IDO1 inhibition improves hippocampal glucose metabolism and rescues hippocampal long-term potentiation in a monocarboxylate transporter–dependent manner. In astrocytic and neuronal cocultures from AD subjects, IDO1 inhibition improved astrocytic production of lactate and uptake by neurons. Thus, IDO1 inhibitors presently developed for cancer might be repurposed for treatment of AD.